This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate
by Zacks Equity Research
Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.
Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why
by Zacks Equity Research
Axsome (AXSM) surges in the past three months owing to its Sunosi acquisition and promising progress on its pipeline candidate.
Has Pliant Therapeutics (PLRX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year.
Pliant Therapeutics, Inc. (PLRX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
by Zacks Equity Research
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 127%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Pliant Therapeutics, Inc. (PLRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study
by Zacks Equity Research
Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
by Zacks Equity Research
Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why
by Zacks Equity Research
bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 106%
by Zacks Equity Research
The mean of analysts' price targets for Pliant Therapeutics, Inc. (PLRX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics
by Zacks Equity Research
Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
by Kinjel Shah
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 0% and 269.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amicus (FOLD) Q2 Earnings Beat, Galafold Sales Miss Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.
Repligen (RGEN) Q2 Earnings and Sales Beat Estimates, Stock Up
by Zacks Equity Research
Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022
Analysts Estimate Kymera Therapeutics, Inc. (KYMR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Kymera Therapeutics, Inc. (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 142%
by Zacks Equity Research
The consensus price target hints at a 142.4% upside potential for Pliant Therapeutics, Inc. (PLRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study
by Zacks Equity Research
Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.
Pliant Therapeutics, Inc. (PLRX) Stock Jumps 159%: Will It Continue to Soar?
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.30% and 12.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?